US8426428B2 - EGFR kinase knockdown via electrophilically enhanced inhibitors - Google Patents

EGFR kinase knockdown via electrophilically enhanced inhibitors Download PDF

Info

Publication number
US8426428B2
US8426428B2 US12/329,445 US32944508A US8426428B2 US 8426428 B2 US8426428 B2 US 8426428B2 US 32944508 A US32944508 A US 32944508A US 8426428 B2 US8426428 B2 US 8426428B2
Authority
US
United States
Prior art keywords
substituted
unsubstituted
compound
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/329,445
Other versions
US20100144705A1 (en
Inventor
Richard Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Principia Biopharma Inc
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Priority to US12/329,445 priority Critical patent/US8426428B2/en
Assigned to PRINCIPIA BIOPHARMA, INC. reassignment PRINCIPIA BIOPHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILLER, RICHARD
Publication of US20100144705A1 publication Critical patent/US20100144705A1/en
Application granted granted Critical
Publication of US8426428B2 publication Critical patent/US8426428B2/en
Application status is Active legal-status Critical
Adjusted expiration legal-status Critical

Links